Research shows Urolithin A significantly enhances heart function in heart failure models — Evidence Review
Published in Science Advances, by researchers from King’s College London, British Heart Foundation
Researched by
— the AI search engine for science
Table of Contents
A new study from King’s College London reports that urolithin A, a compound produced after eating pomegranates and other foods, significantly improved heart function in experimental models of a challenging form of heart failure. Related research generally supports the cardioprotective potential of pomegranate-derived compounds and urolithin A, though most evidence to date comes from animal or cell studies.
- Multiple studies confirm that both pomegranate extracts and metabolites like urolithin A have beneficial effects on heart tissue, including improved relaxation, reduced fibrosis, and antioxidant actions, aligning with the new findings 1 4 5 7 8 10.
- While some clinical trials in humans suggest pomegranate juice and extracts can improve cardiovascular risk factors, direct evidence for urolithin A improving heart failure outcomes in humans is still lacking 1 2 6.
- The new study introduces a novel mechanistic insight—urolithin A activation of PKGlα—for heart muscle relaxation, which complements earlier research on antioxidant, anti-inflammatory, and mitochondrial pathways 8 10 13.
Study Overview and Key Findings
Heart failure with preserved ejection fraction (HFpEF) is a growing health concern, particularly as populations age and chronic conditions like diabetes and obesity become more prevalent. Unlike other forms of heart failure, HFpEF lacks effective treatments because the heart’s pumping ability is maintained, but its capacity to relax and refill is impaired. This study addresses the pressing need for new therapies by investigating urolithin A, a compound formed in the body after consuming pomegranates and similar foods, and its impact on heart function in experimental models.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | King’s College London, British Heart Foundation |
| Journal Name | Science Advances |
| Authors | Jie Su, Yue Zhao, Pierre Coleman, Xiaoping Yang, Mark Holt, Janice Raabe, Friederike Cuello, Ajay Shah, Michael J. Shattock, Min Zhang, Joseph R. Burgoyne |
| Population | Experimental models of heart failure with preserved ejection fraction |
| Methods | Animal Study |
| Outcome | Heart function improvement, relaxation of heart tissue, reduction of fibrosis |
| Results | Urolithin A improved heart function by up to 80% in models. |
Literature Review: Related Studies
To provide context for these findings, we searched the Consensus database of over 200 million research papers. The following queries were used to identify relevant studies:
- pomegranates heart failure treatment
- urolithin A heart function improvement
- natural compounds heart disease therapies
Related Studies Table
| Topic | Key Findings |
|---|---|
| What is the evidence for cardioprotective effects of pomegranate and its metabolites? | - Pomegranate juice and extracts reduce angina and improve cardiovascular markers in patients with ischemic heart disease, and show antioxidant and antifibrotic effects in animal models 1 2 4 5. - Urolithin A and B, metabolites of pomegranate polyphenols, protect against myocardial injury and fibrosis in animal studies, often via antioxidant and anti-inflammatory pathways 7 8 9 10. |
| How does urolithin A affect heart tissue at the molecular and cellular level? | - Urolithin A activates mitochondrial and antioxidant pathways, reduces inflammation, and inhibits fibrosis in heart tissue, with evidence for mechanisms involving Nrf2, SIRT1, and now PKGlα 6 8 10. - Animal studies show urolithin A improves cardiac contractility, relaxation, and reduces markers of cellular stress and tissue remodeling 7 8 10. |
| Are there clinical benefits of pomegranate or its extracts in human cardiovascular health? | - Small clinical trials indicate pomegranate juice or extract can reduce blood pressure, improve antioxidant status, and reduce angina in patients with heart disease, but direct evidence for heart failure treatment in humans is lacking 1 2. - Reviews highlight the potential of dietary polyphenols, including those from pomegranate, as adjuncts for cardiovascular disease prevention and management 3 11 13. |
| What are the broader implications of natural compounds for treating heart failure and fibrosis? | - Natural compounds such as polyphenols and plant extracts show promise for reducing cardiac fibrosis, improving diastolic function, and supporting cardiovascular health, but most evidence comes from preclinical studies 12 13 14 15. - There is growing interest in targeting mitochondrial and oxidative pathways using natural products for heart disease therapy 6 14. |
What is the evidence for cardioprotective effects of pomegranate and its metabolites?
Research has consistently shown that pomegranate juice, extracts, and their gut-derived metabolites provide protective effects in cardiovascular models. These benefits are observed across clinical, animal, and cellular studies, with mechanisms attributed to antioxidant activity, reduction in inflammation, and antifibrotic effects. The new study’s findings that urolithin A improves heart relaxation and reduces fibrosis are therefore well-aligned with previous evidence.
- Human trials demonstrate that pomegranate juice can reduce angina and markers of myocardial injury in heart disease patients 1.
- Pomegranate extracts improve antioxidant status, blood pressure, and lipid profiles in healthy volunteers and animal models 2 4 5.
- Animal and in vitro studies show that urolithin A and B protect against myocardial injury and fibrosis, supporting the new study’s focus on heart tissue relaxation and remodeling 7 8 9 10.
- The breadth of evidence underscores the translational potential for pomegranate-derived compounds in cardiovascular disease, though clinical application for heart failure remains to be established 3.
How does urolithin A affect heart tissue at the molecular and cellular level?
Urolithin A modulates several cellular pathways involved in cardiovascular health. Prior studies have highlighted its role in activating antioxidant defense systems, enhancing mitochondrial function, and inhibiting inflammatory and fibrotic processes in the heart. The current study adds a novel mechanistic insight by identifying PKGlα activation as a key pathway for heart muscle relaxation.
- Urolithin A activates Nrf2 and SIRT1 pathways, leading to reduced oxidative stress, improved mitochondrial function, and decreased tissue damage in animal models 6 8 10.
- Animal studies show that urolithin A administration improves contractility, relaxation kinetics, and calcium handling in heart cells, mirroring the improvements seen in the new study 7 8.
- The new mechanism (PKGlα activation) complements existing knowledge about antioxidant and anti-inflammatory pathways 8 10 13.
- These findings collectively suggest that urolithin A acts at multiple molecular levels to support heart health.
Are there clinical benefits of pomegranate or its extracts in human cardiovascular health?
While preclinical data are promising, clinical studies in humans are limited and somewhat preliminary. Existing trials show improvements in cardiovascular risk factors and symptoms, such as reduced angina and blood pressure, but direct evidence for improvements in heart failure outcomes is still lacking.
- Small randomized controlled trials have found that pomegranate juice reduces angina and serum markers of injury in heart disease patients, supporting a potential role in cardiac protection 1.
- Pomegranate extract supplementation improves antioxidant status, reduces blood pressure, and modulates stress hormone profiles in healthy individuals, but studies in heart failure patients are absent 2.
- Reviews advocate for dietary polyphenols, including those from pomegranate, as preventive or adjunctive strategies for cardiovascular disease, though robust clinical trials specific to heart failure are needed 3 11 13.
- The current study’s focus on urolithin A in experimental models highlights the translational gap that exists for clinical research.
What are the broader implications of natural compounds for treating heart failure and fibrosis?
Natural compounds, especially polyphenols and plant-derived metabolites, are increasingly recognized for their potential in managing cardiac fibrosis and heart failure. These compounds often target mitochondrial function, oxidative stress, and inflammation. However, most evidence for their efficacy comes from animal and cellular models, and only a few have progressed to human trials.
- Screening studies have identified natural compounds with antifibrotic effects, including improvements in diastolic function, in animal models of heart failure 12.
- Reviews and experimental studies point to the cardioprotective effects of plant polyphenols, resveratrol, and herbal extracts, with mechanisms involving oxidative stress reduction and mitochondrial protection 13 14 15.
- The new study fits within a larger body of research exploring naturally derived compounds as potential therapies for complex heart conditions.
- Clinical translation remains a challenge, underscoring the need for more human trials to confirm safety and efficacy.
Future Research Questions
Although the new findings offer promising insights, further investigation is needed to translate these results from experimental models to clinical practice. Key areas for future research include elucidating mechanisms in humans, evaluating long-term safety and efficacy, and understanding how dietary or supplemental interventions can be optimized.
| Research Question | Relevance |
|---|---|
| Does urolithin A improve heart function in patients with HFpEF? | Direct human data are lacking; confirming efficacy and safety in individuals with heart failure with preserved ejection fraction is critical before clinical application 1 2 6. |
| What are the long-term effects and safety profile of urolithin A supplementation in humans? | While short-term studies suggest good safety, the long-term effects and optimal dosing of urolithin A require systematic study to ensure safe therapeutic use 6. |
| How do dietary patterns and gut microbiota influence urolithin A production and bioavailability? | Urolithin A is produced by gut microbes after consuming ellagitannin-rich foods; individual variation in microbiota may impact therapeutic effectiveness 3 6. |
| Can combining urolithin A with other natural compounds enhance cardioprotective effects in heart failure? | Investigating synergistic effects with other polyphenols or plant extracts may optimize treatment strategies for complex heart conditions 13 14 15. |
| What molecular mechanisms mediate urolithin A’s effects on heart muscle relaxation and fibrosis? | Further studies are needed to detail how urolithin A activates pathways like PKGlα, SIRT1, and Nrf2, and how these contribute to improved cardiac function 8 10. |